BEIJING--(BUSINESS WIRE)--China Medical Technologies (NASDAQ: CMED), a leading China-based medical device company that develops, manufactures and markets high intensity focused ultrasound products and advanced in-vitro diagnostic systems, today announced that it has entered into a definitive acquisition agreement to purchase the fluorescent in situ hybridization (“FISH”) business of Supreme Well Investments Limited and Molecular Diagnostics Technologies Limited (the “Sellers”), which are BVI-incorporated entities with operations in the U.S., Hong Kong and China. FISH is a type of hybridization in which a DNA probe is labeled with fluorescent dye so that it can be seen with a microscope. China Medical intends to develop and commercialize the FISH technology in China for the diagnosis of prenatal and postnatal disorders as well as various cancers through laboratory evaluation and analysis of bodily fluids and tissues.
